significantly delayed growth of the Caki-1 renal cell carcinoma model, whereas neither agent was active alone. These data demonstrate that tasisulam has a unique, dual-faceted mechanism of action involving mitotic catrostrophe and anti-angiogenesis, a phenotype distinct from conventional chemotherapies and published anti-cancer agents.
Introduction
Despite the massive resources expended over the past 20 years and a steadily declining death rate since the 1990s, cancer remains the second leading cause of death in the United States (1-2). The human genome project has provided hope for a new era of cancer therapeutics by identifying novel molecular targets for drug discovery (3) (4) (5) . Despite the promise of genomics-centered drug discovery, it is likely that phenotypic-based approaches will continue to play a valuable, complementary role through interrogation of the cell as a target (6) (7) (8) . Indeed many of today's standard of care anti-cancer agents were identified using phenotypic approaches (9) .
LY573636-sodium, hereafter referred to as tasisulam, is small molecule acyl-sulfonamide that is the product of a phenotypic drug screen of >14,000 compounds. A requirement of the screen was to identify compounds that had approximately a hundred fold margin of activity between cancerous and nontransformed normal cells. In vitro, tasisulam is a potent antiproliferative compound (free drug EC 50 typically in the low µM range) and displays preferential cancer cell death relative to normal, untransformed human cell lines (10) (11) . Furthermore, NCI COMPARE analysis indicates that tasisulam possesses a unique mechanism of action relative to other agents (10, 12) . In humans, tasisulam has demonstrated activity in several different tumor subtypes, and clinical studies are ongoing or completed in soft tissue sarcoma, ovarian cancer, acute myeloblastic leukemia, metastatic breast cancer, non-small cell lung cancer, and renal cancers (13) (14) (15) . In hematological malignancy cell lines, tasisulam induced apoptosis through induction of the caspase-9 dependent intrinsic apoptosis pathway, possibly resulting from a direct effect on mitochondrial processes leading to upregulation of reactive oxygen species (ROS) (16) . However, the cellular mechanism(s) underlying these effects were not well understood.
We have expanded the pre-clinical investigation of tasisulam into a wide variety of solid tumor cell lines, with a particular focus on elucidating the cellular processes underlying the anticancer activity of this compound. Surprisingly, tasisulam disrupted two seemingly distinct processes in cancer cell lines, neither of which appears to cause a primary induction of ROS.
The first involved induction of the intrinsic apoptosis pathway in a cell cycle-dependent fashion.
Using high content imaging (HCI)-based subpopulation analysis (17) (18) we demonstrated that G2/M accumulation leads to caspase-3 activity and subsequent cell death. The second involved tasisulam-mediated effects on tumor vasculature. Tasisulam displayed both in vitro and in vivo anti-angiogenic effects, without inhibiting the proximal growth factor/receptor signaling or inducing endothelial cell death. In addition, tasisulam promoted vascular normalization by stabilizing the existing vasculature, reducing vessel tortuosity, and reducing hypoxia in vivo (19) .
Although identification of the precise cellular target(s) will require additional study, these results suggest that the broad activity of tasisulam in cancer pre-clinical models is mediated by both cytotoxic and anti-angiogenic effects. 
Materials and Methods

In Vitro Cancer Cell Experimentation
Cells (non-NCI COMPARE panel) were acquired from ATCC (Manassas, VA) and cultured according to ATCC guidelines and plated in growth medium for 24 hours prior to treatment.
Cell authenticity was verified by STR genotyping at RADIL no more than 6 months prior to drug testing (20). Cells were plated @ 500,000 cells/10 mL into 10 cm dishes for flow cytometry which was performed with a Beckman Coulter FC5 and cell cycle was determined using MOD fit.
For Western blotting, nitrocellulose membranes were blocked in Tris-buffered saline, 0.1% Tween-20 and 5% nonfat dry milk, probed for cleaved caspases-3 or -9, PARP/cleaved PARP (Cell Signaling Technology) and then exposed to secondary antibody for 1 hour at 25 o C.
Proteins were visualized with Super Signal® West Femto enhanced chemiluminescence detection (ThermoFisher) and imaged with a Bio-Rad ChemiDoc™ XRS. For HCI, all procedures are previously described (18) . For cell viability, cellular ATP production was measured by Cell Titer Glo® Assay (Promega). For assessment of in vitro biochemical proangiogenic receptor tyrosine kinase inhibitory activity, tasisulam was tested at Cerep (Poitiers, France) and Millipore (Billerica, MA) per industry accepted and validated guidelines).
In vitro Endothelial Cell Experimentation
For assessment of HUVEC migration, HUVECs (45,000/well) were plated in black 96 well collagen I plates (BD) and incubated overnight at 37 0 C in 5%CO 2 . Cells were labeled with 3.6uM CMFDA (Invitrogen) for 30 minutes in serum free medium whereupon complete growth medium was replenished and incubated for 30 minutes. A scratch was made in each well using a pintool affixed to a MultiMek robot 96 well head. Cells were then washed using 200ul normal PBS. 100ul serum free medium was then added to each well. Cell migration was detected using the Acumen Explorer for day 0 (baseline) data collection. An additional 100ul 10% serumcontaining medium with 2X compound was added into each well after imaging. The plate was cultured overnight and imaged to collect endpoint data. Migration was measured using the difference between endpoint and baseline readings for each well. 
Tumor Tissue Immunofluorescence and Imaging
Five days post treatment, xenografts were excised and placed into zinc-tris fixative.
After 24 hours, tumors were trimmed, routinely processed, embedded in paraffin blocks and four micron sections were made. Slides were baked at 60 calculated as the percentage of total tissue area (Hoechst positive) that is also CD31 positive. % Pericyte Coverage of Vessels was calculated as the percentage of total CD31 area that was also colocalized with SMA staining. % Hypoxia Area was calculated as the percentage of total tissue area that is also GLUT1 positve. Mean Tortuosity Index was calculated as the % of large vessels/% of small vessels. Vascular Normalization Index was calculated as (Pericyte Coverage of Vessels)/(MVD*% Hypoxia Area*Mean Tortuosity Index) relying on both direct and surrogate markers for these parameters as explained under "Results". Quantitative data comparisons of treatment groups were performed using the Dunnett's analysis in JMP statistics software (SAS).
Tumor Histopathology and Immunohistochemistry (IHC)
Xenografts were formalin fixed, trimmed and embedded in paraffin. Three micron sections were immunohistochemically labeled using an autostainer for phosphohistone H3-serine 10 (pHH3) with a rabbit polyclonal primary antibody (Upstate) at a concentration of 1 µg/mL without antigen retrieval and with 3, 3'-diaminobenzidine as chromagen. Sections were counterstained with hematoxylin. Additional sections were stained with hematoxylin and eosin (H&E). Digital images of the immunolabeled slides were captured with the Scan Scope XT (Aperio) and evaluated using the Spectrum software (Aperio) positive pixel count algorithm. Representative in vitro anti-proliferation curves in the Calu-6 non small cell lung carcinoma (EC 50 = 10 µM) and A-375 melanoma models (EC 50 = 25 µM) are shown (Fig. 1A) . (Fig. 1B, inset) HCI subpopulation analysis revealed that only those cells with increased DNA content displayed activated caspase-3, with the extent of induction proportional to the increase in DNA content, nuclear area and pHH3 (Fig. 2B) . Quantitation of G2/M accumulation corroborated FACS data whereby tasisulam's effects were maximal after 48 hours (two cell doublings), further strengthening the hypothesis that tasisulam induces cancer cell apoptosis through a cell cycle related mechanism.
Tasisulam inhibited endothelial cell proliferation in vitro.
In the original phenotypic screen, compounds were required to have a significant margin to apoptosis in malignant vs. normal cells. Tasisulam caused non-apoptotic growth arrest in human umbilical vein endothelial cells (HUVEC), prompting further study in other endothelial cell types. ECFCs treated with tasisulam and analyzed in a HCI proliferation and apoptosis assay showed dramatic decreases in the proliferation marker Ki67 at concentrations above 2 μM total tasisulam (~0.6 µM free drug), similar to the effect observed with the multi-targeted receptor tyrosine kinase inhibitor sunitinib (Fig. 3A) . However, neither tasisulam nor sunitinib induced endothelial apoptosis, as measured by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). This was in sharp contrast to the microtubule targeting agent, nocodazole, which was both anti-proliferative and pro-apoptotic (Fig. 3A) . The antiproliferative effect of tasisulam was not limited to ECFCs and was also observed with endothelial cells of different origins and primary human fibroblasts (data not shown). Furthermore, in HUVECs there were no significant changes in cell cycle distribution as determined by FACS (Table S2) 
Tasisulam inhibited in vitro endothelial cord formation and in vivo angiogenesis.
Since endothelial proliferation is a process critical for angiogenesis, tasisulam was next assessed for inhibition of in vitro endothelial cord formation, a surrogate assay that models key morphogenic features of blood vessel formation (21) . Tasisulam inhibited VEGF-, FGF-and EGFinduced cords in a concentration dependent manner with EC 50 s of 47 ηM, 103 ηM and 34 ηM, respectively (Fig. 3B, C) . To determine if tasisulam interfered with acute proximal growth factor receptor-related signaling, a cell impedance assay was employed. Changes in impedance as a result of growth factor-induced morphological changes are a quantitative measure of receptor tyrosine kinase pathway activity (22) . VEGF causes a relaxation of the junctions between cells and hence less resistance to electrical conductivity, expressed here as a decrease in impedance.
EGF and FGF cause a slight increase in cell-to-cell pressure and hence a slight increase in impedance. Sunitinib, an approved angiogenesis inhibitor, completely blocked the response to VEGF, but not EGF or FGF. Tasisulam did not inhibit VEGF, FGF or EGF induced impedance changes indicating that it did not interfere with acute proximal growth factor/receptor signaling (Table 1) , consistent with the fact that tasisulam does not inhibit these kinases in vitro (data not shown). In addition, tasisulam is not inhibitory to HUVEC migration in vitro, suggesting that effects on cord formation involve an as yet unexplained mechanism (data not shown).
To determine if tasisulam promotes an anti-angiogenic effect in vivo, a Matrigel® plug model of neoangiogenesis (23) at both 25 and 50 mg/kg (corresponding to clinically relevant doses) caused a significant reduction in hemoglobin content (Fig. 4B) and mean blood vessel density by IHC labeling of Matrigel® plugs (Fig. 4C) . A similar effect was seen in animals treated with a therapeutically relevant dose of sunitinib (Fig. 4C) (Fig. 5B) . As mentioned above, the strong G2/M accumulation is likely due to the increased number of 4N cells within an untreated, asynchronous Calu-6 cell population. H&E staining of tumor sections also showed increased DNA fragmentation and other apoptosis-associated cellular changes in tasisulam-treated tumors compared to controls (Fig. 5B, bottom panels, 
similar anti-tumor efficacy across a range of in vivo xenografts, including colorectal (HCT-116), melanoma (A-375), gastric (NUGC-3), leukemia (MV-4-11), pancreatic (QGP-1) (Supplemental Figures S3-S4) , and multiple tumorgrafts of widely varying histology (data no shown)(24).
To determine if there was a link between anti-tumor activity, indicators of G2/M accumulation/apoptosis, and anti-angiogenic activity in vivo, multiplexed immunofluorescence tissue imaging of tasisulam-and control-treated xenografts was performed, using a panel of cellular markers of tumor-associated vascularization. These, in turn, were used to assess the degree of vascular normalization, characterized by reduced vessel density, increased pericyte coverage of vessels, decreased vessel tortuosity, and decreased tumor hypoxia (19) . Each feature was individually quantitated using image processing algorithms to generate a "normalization index" (see Materials and Methods). Tumors were labeled with Hoechst, anti-CD31 to visualize endothelial cells/blood vessels, anti-smooth muscle actin to visualize myofibroblasts/pericytes, and anti-GLUT1 as a surrogate marker for tissue hypoxia (25) (26) .
While GLUT-1 does not directly measure hypoxia, in many xenograft models (including the Calu6 model) it is an accurate surrogate of hypoxia. Examination of control-and tasisulamtreated Calu-6 tumors revealed that tasisulam induced changes in several vascular morphological parameters, consistent with a vascular normalization phenotype. These changes included dose-dependent decreases in vessel density and vessel tortuosity, and trends for an increase in pericyte coverage of vessels, decrease in hypoxia and an overall increased normalization index (Fig. 5C ). Similar phenotypic effects were observed in the A-375 melanoma (data not shown). 
Because tasisulam and sunitinib modulated the vasculature through apparently distinct mechanisms (Table 1) , the activity of these agents, alone or together, was explored in the human renal cell carcinoma mouse xenograft model Caki-1. 10 mg/kg sunitinib displayed no tumor growth delay, while both 25 mg/kg tasisulam and the tasisulam/sunitinib combination showed a modest effect out to ~ day 50. Beyond day 50, the combination displayed a durable, statistically significant tumor growth delay (minimal p<0.01 from day 26 onward) ( (6) . Because tasisulam had no effect on DNA synthesis (Fig 2B and data not shown) , it is possible mitotic effects are exerted through interaction with a novel target protein(s) prior to the G2 checkpoint, a hypothesis supported by the delay in cell cycle progression noted in double thymidine blocked Calu-6 cells treated with tasisulam immediately after synchronization ( Figure S2 ).
Angiogenesis is a biological process retained by tumors that is critical for tumor growth.
While the field of anti-angiogenic therapy was established largely on the basis of Folkman's hypothesis to "starve" tumors of their blood supply (27) (28) , the emerging concept of "vascular normalization" has gained momentum (19) . Normalization is a process by which a dense, highly tortuous and poorly delivering tumor vasculature is converted to one that is more sparse, yet very stable, mature (highly invested in pericytes), organized and functional (19) . Anti-angiogenic Further, tasisulam HCI fingerprints were clearly distinct from previously published HCI fingerprints of anti-mitotic agents that exhibit G2 phase-specific characteristics such as significantly increased nuclear area in conjunction with 4N DNA content and only slightly changed variation in Hoechst DNA staining(6-7). Altogether, these findings result in a unique phenotypic MOA for tasisulam, characterized by cell cycle-dependent apoptosis in a broad range of cancer cell lines, and anti-angiogenic effects in the absence of endothelial cell apoptosis or G2/M accumulation.
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